Reuters logo
2 months ago
BRIEF-Novo Nordisk says Tresiba showed significant reduction in rates of severe hypoglycaemia compared to insulin glargine
June 12, 2017 / 9:25 PM / 2 months ago

BRIEF-Novo Nordisk says Tresiba showed significant reduction in rates of severe hypoglycaemia compared to insulin glargine

June 12 (Reuters) - Novo Nordisk A/S:

* tresiba showed no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine

* Novo Nordisk says trial demonstrated that tresiba met primary endpoint of non-inferiority compared with insulin glargine u100 for major adverse cv events

* results from secondary endpoints of trial showed significant reduction in rate of severe and nocturnal severe hypoglycaemia with tresiba versus insulin glargine u100

* Novo Nordisk says safety profile of tresiba in devote was generally consistent with previous tresiba clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below